JARVISDHL Screening Tools

Not yet recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2027

Conditions
Coronary Artery Disease
Interventions
DIAGNOSTIC_TEST

Ocular Imaging

The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.

OTHER

Questionnaires

3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.

Trial Locations (1)

169609

National Heart Centre Singapore, Singapore

All Listed Sponsors
collaborator

Singapore Eye Research Institute

OTHER

lead

National Heart Centre Singapore

OTHER

NCT05626517 - JARVISDHL Screening Tools | Biotech Hunter | Biotech Hunter